Upadacitinib may benefit patients with PsA
25 Jun 2021
byAudrey Abella
The oral Janus kinase inhibitor upadacitinib – which has gained approval for the treatment of rheumatoid arthritis (RA) – showed potential for treating individuals with psoriatic arthritis (PsA) who have insufficient response to nonbiologic disease-modifying antirheumatic drugs, according to the phase III SELECT-PsA 1 trial.
